Mylan and Pfizer’s Upjohn combine to improve patient outcomes with iconic branded medicines, generics and biosimilars.
Mylan and Pfizer’s Upjohn combine to improve patient outcomes with iconic branded medicines, generics and biosimilars.
Today marks the launch of Viatris, a new global healthcare company formed through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Our global portfolio comprises more than 1,400 molecules, including best-in-class brand names that Australian doctors regularly prescribe. We also supply generics, including branded and complex generics, biosimilars and OTC treatments.
With your permission, we would like to keep you up to date about our medications and the diseases they treat. Please click here to receive:
- Information about our Australian brands;
- Safety information;
- Supply information;
- Treatment insights;
- Sample alerts;
- Patient handouts;
- And more.
We are committed to making the creation of Viatris seamless for you and to ensuring that our operations and support continue uninterrupted. Should there be any changes, we will inform you as quickly as possible.
Special message to doctors from Australia GM Sylvain Vigneault:
At Viatris, we see healthcare not as it is, but as it should be. Our mission is to empower people worldwide to live healthier at every stage of life. We do so via:
- Access – Providing high quality, trusted medicines to patients regardless of geography or circumstance;
- Leadership – Advancing sustainable operations and innovative solutions to improve patient health; and
- Partnership – Leveraging our collective expertise to connect people to products and services.
From cardiovascular health to oncology, we offer quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases.
Our diverse and differentiated portfolio, supported by world-class commercial and regulatory expertise, delivers trusted, quality medicines that treat nine out of 10 of the World Health Organization’s (WHO) leading causes of death, and more than 200 of our medicines are on the WHO Essential Medicines List.
We have approximately 50 manufacturing facilities around the world and our global team includes 2,500 scientists, 1,000 regulatory experts and over 600 medical and product safety professionals.
In Australia, our manufacturing plant at Carole Park in Queensland is the largest local supplier by volume of prescription tablets and capsules to the Pharmaceutical Benefits Scheme and supplies more than 40 export markets.
Please be assured that as we continue to integrate our two companies, you should expect that it will be business as usual.
While this week marks our first as Viatris, rebranding into a new company takes time, which means you may continue to see our former company names on our products and other materials for some time.
To learn more about our new company, please read our factsheet and visit Viatris.com. You can also stay connected with us on Twitter (@ViatrisInc), LinkedIn and YouTube
Please click here to stay connected with us as we embark on this new journey
We look forward to continuing our valuable partnership with prescribers, working toward our common goal of empowering people worldwide to live healthier.
Yours in good health,
Sylvain Vigneault
Country Manager Australia
Copyright © 2020 Viatris Inc. All rights reserved.
Alphapharm Pty Ltd (trading as Mylan Australia) (ABN 93 002 359 734), Mylan Health Pty Ltd (ABN 29 601 608 771), and Upjohn Australia Pty Ltd (ABN 50 629 389 911). Level 1, 30-34 Hickson Road, Millers Point NSW 2000. Tel 1800 314 527.
